FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037258736> ?p ?o ?g. }

• W2037258736 endingPage "615" @default.
• W2037258736 startingPage "614" @default.
• W2037258736 abstract "‘Know thyself’ From the Temple of Apollo at Delphi. Anti-cytokine autoantibodies are increasing their visibility as important mechanisms of disease pathogenesis. Pulmonary alveolar proteinosis (PAP) can be caused by anti-GM-CSF autoantibodies,1 pure red-cell aplasia can be caused by anti-erythropoietin autoantibodies,2,3 disseminated non-tuberculous mycobacterial infections can be caused by anti-interferon (IFN)-gamma autoantibodies4,5,6,7 and staphylococcal infections have been associated with anti-IL-6 autoantibodies.8 Autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED) syndrome is caused by mutations in the autoimmune regulator (AIRE),9 leading to loss of thymic deletion of autoreactive T cells with multiple autoimmune consequences such as hypoparathyroidism, diabetes, and adrenal failure.10 Interestingly, anti-cytokine autoantibodies are extremely common in APECED, mostly directed against type I IFNs.11 However, one of the puzzling components of APECED is severe chronic mucocutaneous candidiasis (CMC). APECED patients are not susceptible to other overt infections, and even CMC remains blocked in the mucosa. In the February 15, 2010 issue of the Journal of Experimental Medicine, Puel et al.12 and Kisand et al.13 have offered elegant explanations of why CMC occurs in APECED: high-titer, neutralizing autoantibodies to the T-cell cytokines that regulate mucosal antibacterial and antifungal activity, IL-17 and IL-22. These cytokines were good targets for involvement in CMC: STAT3-deficient hyper IgE (Job's) syndrome,14,15 dectin-1 deficiency,16 CARD9 deficiency,17 and to a lesser extent, IL-12 receptor β1 deficiency,14 all have CMC and varying degrees of Th17 impairment, linking this pathway to mucosal candidiasis. Puel et al. examined 33 APECED patients and identified antibodies to IL-17A, IL-17F, and IL-22 in all the 33 APECED patients tested, 29 of whom also had CMC; healthy controls had neither those autoantibodies nor CMC.12 They confirmed the function of the anti-IL-17A antibody by inhibiting IL-6 production from IL-17 responsive fibroblasts.18 Kisand et al. examined 162 APECED patients and found anti-IL-17 A, IL-17F, and IL-22 autoantibodies in up to 90% of cases, strongly associated with CMC.13 Titers of autoantibodies to IL-17 and IL-22 actually declined with age in APECED, whereas titers of autoantibodies against type 1 IFNs, did not. Exploring specificity, Kisand et al. noted that homozygous cases of the common AIRE mutation R257X were always associated with anti-IL-17 and anti-IL-2 autoantibodies and CMC, whereas other mutations were more variable. They did not find autoantibodies to IL-17 or IL-22 in cases of CMC without other features of APECED or AIRE mutation, but they did find these autoantibodies in two out of 35 patients with thymoma and CMC.13 Therefore, CMC with immune dysregulation is often associated with anti-cytokine autoantibodies. Kisand et al. and Puel et al. found only IgG autoantibodies in this syndrome limited to the mucosa, but not in secreted IgA. What are we to make of these exciting observations? Although anti-cytokine autoantibodies leading to immunodeficiency have been described earlier, they have been in the setting of rare infections and are still unassociated with specific mutations. Autoantibodies provide novel facets to PAP, nontuberculous mycobacteria, and staphylococcal infections, but we are still woefully ignorant about why the antibodies happen or what really to do about them. In contrast, Kisand et al. and Puel et al. describe pathogenic autoantibodies in the context of a disease with recognized mutations that was recognized earlier. Kisand et al. even point out the genotype--phenotype associations with a specific mutation in AIRE. This is a first pass at identifying fundamental mechanisms around the generation of autoantibodies in general, and specific ones in particular. Now that it is clear that certain anti-cytokine autoantibodies result in opportunistic infections, we need to address the mechanisms of pathogenicity of these autoantibodies. Functional demonstration of neutralization of cognate cytokines by certain autoantibodies is complemented by the knowledge of genetic defects in the cytokine pathways leading to similar infections. For instance, defects in the IFNγ/IL-12 signalling pathways (IFNGR1, IFNGR2, STAT1, IL-12B [p40], IL-12RB1, IKBKG/NEMO) lead to disseminated mycobacterial infection.19 Mutations in the STAT3/IL-6 signalling pathways (STAT3, TYK2)6,20 lead to severe staphylococcal skin infections. In contrast, the genetically defined pathways leading to CMC, other than those seen with profound T-lymphocyte dysfunction, include STAT3, DOCK8, Tyk2, IL-12Rβ1, as well as dectin-1, CARD9, and AIRE. Uniting many of these pathways are defects in IL-17 and IL-22 generation and response, giving further weight to the observations of IL-17 and IL-22 blockade in AIRE deficiency. As both Puel et al. and Kisand et al. report a few instances of autoantibodies without CMC, and there are many instances of CMC outside of APECED without autoantibodies, autoantibodies to IL-17 and IL-22 are likely not the complete story. Single anti-cytokine autoantibodies may be necessary and sufficient for some diseases (for example, anti-GM-CSF autoantibodies in PAP), but others may require combinations of factors or perhaps multiple autoantibodies acting in concert. The potential exists for an indefinite number of autoantibodies to be involved on both sides of disease causation. Autoantibodies to antimicrobial peptides, hormones and/or cell surface receptors are likely to be involved in the disease. In addition, it is possible that autoantibodies could actually facilitate or exacerbate inflammation by inhibiting anti-inflammatory cytokines, such as IL-10. Therefore, broad searches for etiologies of new and old syndromes will have to incorporate an increasingly dizzying array of etiologic possibilities. The association of specific diseases with only a particular set of anti-cytokine autoantibodies is a remarkable feature of these entities. Although thymoma and APECED share high rates of anti-IFNα autoantibodies, only thymoma shows IL-12 autoantibodies,21 but neither disease has anti-IFNγ or anti-GM-CSF autoantibodies. Despite the challenges of identifying and characterizing anti-cytokine autoantibodies in the disease, they open exciting new possibilities for treatment. Plasmapheresis and intravenous immune globulin have been tried in many autoantibody-mediated diseases, but their results are typically modest. The CD20+ B-cell-targeted therapeutic antibody, rituximab, has been used in small series in a variety of diseases mediated by autoantibodies with encouraging results.22,23,24 Autoantibodies to cytokines represent an emerging layer of immune regulation. Unlike primary congenital immunodeficiencies, these may develop over time, wax and wane, and change in titer or avidity. Antibodies targeting a given cytokine can be found incidentally in healthy hosts and associated with disease ranging from mild to severe. Whether involved in normal cytokine homeostasis or pathology, anti-cytokine autoantibodies have the proven potential to modulate cytokine pathways. The new work highlighting the functions of autoantibodies to IL-17 and IL-22 in CMC in APECED is a strong start in an exciting direction. The authors declare no conflict of interest." @default.
• W2037258736 created "2016-06-24" @default.
• W2037258736 creator A5043605887 @default.
• W2037258736 creator A5056552919 @default.
• W2037258736 date "2010-06-15" @default.
• W2037258736 modified "2023-09-27" @default.
• W2037258736 title "Anti‐cytokine autoantibodies explain some chronic mucocutaneous candidiasis" @default.
• W2037258736 cites W1555469017 @default.
• W2037258736 cites W1965206234 @default.
• W2037258736 cites W2048548715 @default.
• W2037258736 cites W2065054549 @default.
• W2037258736 cites W2082936552 @default.
• W2037258736 cites W2083737302 @default.
• W2037258736 cites W2086332067 @default.
• W2037258736 cites W2086437884 @default.
• W2037258736 cites W2101524137 @default.
• W2037258736 cites W2104497596 @default.
• W2037258736 cites W2105815838 @default.
• W2037258736 cites W2107922239 @default.
• W2037258736 cites W2115055179 @default.
• W2037258736 cites W2116622733 @default.
• W2037258736 cites W2125573161 @default.
• W2037258736 cites W2136745465 @default.
• W2037258736 cites W2154965207 @default.
• W2037258736 cites W2162721157 @default.
• W2037258736 cites W2163694362 @default.
• W2037258736 cites W2164082708 @default.
• W2037258736 cites W2164500783 @default.
• W2037258736 cites W2165214298 @default.
• W2037258736 cites W2317276018 @default.
• W2037258736 cites W2338669471 @default.
• W2037258736 doi "https://doi.org/10.1038/icb.2010.72" @default.
• W2037258736 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4103911" @default.
• W2037258736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20548324" @default.
• W2037258736 hasPublicationYear "2010" @default.
• W2037258736 type Work @default.
• W2037258736 sameAs 2037258736 @default.
• W2037258736 citedByCount "21" @default.
• W2037258736 countsByYear W20372587362012 @default.
• W2037258736 countsByYear W20372587362013 @default.
• W2037258736 countsByYear W20372587362014 @default.
• W2037258736 countsByYear W20372587362017 @default.
• W2037258736 countsByYear W20372587362019 @default.
• W2037258736 countsByYear W20372587362020 @default.
• W2037258736 countsByYear W20372587362021 @default.
• W2037258736 countsByYear W20372587362022 @default.
• W2037258736 crossrefType "journal-article" @default.
• W2037258736 hasAuthorship W2037258736A5043605887 @default.
• W2037258736 hasAuthorship W2037258736A5056552919 @default.
• W2037258736 hasBestOaLocation W20372587361 @default.
• W2037258736 hasConcept C142724271 @default.
• W2037258736 hasConcept C156662089 @default.
• W2037258736 hasConcept C159654299 @default.
• W2037258736 hasConcept C163764329 @default.
• W2037258736 hasConcept C203014093 @default.
• W2037258736 hasConcept C2776422140 @default.
• W2037258736 hasConcept C2778690821 @default.
• W2037258736 hasConcept C2779134260 @default.
• W2037258736 hasConcept C71924100 @default.
• W2037258736 hasConceptScore W2037258736C142724271 @default.
• W2037258736 hasConceptScore W2037258736C156662089 @default.
• W2037258736 hasConceptScore W2037258736C159654299 @default.
• W2037258736 hasConceptScore W2037258736C163764329 @default.
• W2037258736 hasConceptScore W2037258736C203014093 @default.
• W2037258736 hasConceptScore W2037258736C2776422140 @default.
• W2037258736 hasConceptScore W2037258736C2778690821 @default.
• W2037258736 hasConceptScore W2037258736C2779134260 @default.
• W2037258736 hasConceptScore W2037258736C71924100 @default.
• W2037258736 hasIssue "6" @default.
• W2037258736 hasLocation W20372587361 @default.
• W2037258736 hasLocation W20372587362 @default.
• W2037258736 hasLocation W20372587363 @default.
• W2037258736 hasLocation W20372587364 @default.
• W2037258736 hasOpenAccess W2037258736 @default.
• W2037258736 hasPrimaryLocation W20372587361 @default.
• W2037258736 hasRelatedWork W1526946356 @default.
• W2037258736 hasRelatedWork W1977761485 @default.
• W2037258736 hasRelatedWork W1981431233 @default.
• W2037258736 hasRelatedWork W2021554541 @default.
• W2037258736 hasRelatedWork W2037468041 @default.
• W2037258736 hasRelatedWork W2088428906 @default.
• W2037258736 hasRelatedWork W2317914672 @default.
• W2037258736 hasRelatedWork W2956245133 @default.
• W2037258736 hasRelatedWork W2186743529 @default.
• W2037258736 hasRelatedWork W2739170588 @default.
• W2037258736 hasVolume "88" @default.
• W2037258736 isParatext "false" @default.
• W2037258736 isRetracted "false" @default.
• W2037258736 magId "2037258736" @default.
• W2037258736 workType "article" @default.